Study guide
3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines)
Medical Council of Canada Qualifying Examination Part I MCCQE Part I
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice
1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics
2 Chapter 2: Population Health, Health Promotion & Preventive Care
2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada
3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems
3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions
4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology
4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers
5 Chapter 5: General Surgery, Orthopedics, & Emergency Care
5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition
6 Chapter 6: Pediatrics & Adolescent Health
6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management
7 Chapter 7: Obstetrics & Gynecology
7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation
8 Chapter 8: Psychiatry & Mental Health
8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)
9 Chapter 9: Neurology, Rheumatology, & Dermatology
9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine
10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice
10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety
3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines)
Key Takeaways Explain This Topic AI
Canadian Thoracic Society (CTS) asthma guidelines recommend anti-inflammatory reliever therapy (low-dose ICS-formoterol as needed) across all severity steps rather than SABA monotherapy to prevent severe exacerbations.
Asthma diagnosis requires objective documentation of reversible airflow obstruction: post-bronchodilator FEV1 improvement of ≥12% AND ≥200 mL, or peak expiratory flow (PEF) variability >20%, or positive methacholine challenge (PC20 ≤8 mg/mL).
COPD diagnosis requires spirometry showing post-bronchodilator FEV1/FVC <0.70; dual LAMA + LABA bronchodilation is preferred initial maintenance therapy for symptomatic patients.
COPD exacerbation target oxygen saturation is strictly 88-92% to avoid hypercapnic respiratory drive suppression; systemic steroids (prednisone 40 mg for 5 days) and antibiotics (if purulence present) improve recovery.
Non-Invasive Positive Pressure Ventilation (BiPAP) is first-line intervention for acute hypercapnic respiratory failure (Type II) in COPD with pH 7.25-7.35.
Last updated: July 2026
3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines)
Quick Summary: Asthma diagnosis requires spirometric reversibility (FEV1 increase ≥12% and ≥200 mL). CTS guidelines mandate Anti-Inflammatory Reliever (AIR / SMART) therapy with low-dose ICS-formoterol as needed over SABA monotherapy. COPD diagnosis requires post-bronchodilator FEV1/FVC <0.70; dual LAMA+LABA is first-line. In AECOPD, target SpO2 is 88–92% to avoid CO2 retention, and BiPAP is first-line for hypercapnic respiratory failure.
Asthma Diagnosis & Management (CTS Guidelines)
Asthma is a chronic inflammatory disorder of the airways characterized by hyperresponsiveness, mucosal edema, and variable airflow obstruction.
Objective Diagnostic Criteria
To establish a diagnosis of asthma, clinical symptoms (wheezing, shortness of breath, chest tightness, cough) must be accompanied by objective evidence of variable airflow obstruction :
Diagnostic Test Criterion Confirming Asthma Diagnosis
Spirometry with Reversibility Post-bronchodilator (after 200–400 mcg salbutamol) increase in FEV1 of ≥ 12% AND ≥ 200 mL
Peak Expiratory Flow (PEF) Diurnal PEF variability > 20% over a 2-week monitoring period
Methacholine Challenge Test PC20 ≤ 8 mg/mL (provocative concentration causing a 20% drop in FEV1); high negative predictive value
- Exercise Challenge Test Post-exercise drop in FEV1 of ≥ 10% AND ≥ 200 mL
- Fractional Exhaled Nitric Oxide (FeNO) FeNO > 25–50 ppb supports eosinophilic airway inflammation
- CTS Stepwise Management (SMART / AIR Paradigm)
Critical Guideline Shift: Canadian Thoracic Society (CTS) guidelines state that SABA monotherapy (salbutamol alone) is NO LONGER RECOMMENDED for initial or maintenance asthma management. SABA monotherapy increases severe exacerbation and mortality risk. Instead, anti-inflammatory reliever (AIR) therapy incorporating an Inhaled Corticosteroid (ICS) is mandated across all steps.
Track 1 (Preferred - Maintenance and Reliever Therapy / MART): Uses a single inhaler containing Low-dose ICS + Formoterol (e.g., Budesonide/Formoterol) as needed for symptom relief in Steps 1–2, and as both daily maintenance AND reliever in Steps 3–4.
Track 2 (Alternative): SABA (Salbutamol) as needed for symptom relief PLUS regular daily maintenance ICS (low, medium, or high dose).
Step 5 (Severe Asthma): Add LAMA (Tiotropium) or phenotype-guided Biologics (Anti-IgE: Omalizumab; Anti-IL5/5R: Mepolizumab, Benralizumab; Anti-IL4R: Dupilumab).
Management of Acute Severe Asthma Exacerbations
Oxygen: Target SpO2 93–95%.
Inhaled Bronchodilators: Continuous or frequent nebulized SABA (Salbutamol 5 mg) + SAMA (Ipratropium bromide 0.5 mg) q20min for the first hour.
Systemic Corticosteroids: Oral Prednisone 40–50 mg daily for 5 days (or IV Methylprednisolone 1 mg/kg q6h if unable to tolerate oral).
IV Magnesium Sulfate: 2 g IV over 20 minutes for severe exacerbations refractory to initial bronchodilators.
COPD Diagnosis & Management (CTS Guidelines)
Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent, progressive airflow limitation resulting from chronic bronchitis or emphysema, predominantly driven by cigarette smoking.
Diagnosis & Severity Grading
Diagnostic Threshold: Post-bronchodilator FEV1/FVC < 0.70 (fixed ratio) on spirometry confirms non-reversible airflow obstruction.
Severity Classification (Based on Post-Bronchodilator FEV1 % Predicted):
- GOLD 1 (Mild): FEV1 ≥ 80% predicted
- GOLD 2 (Moderate): 50% ≤ FEV1 < 80% predicted
- GOLD 3 (Severe): 30% ≤ FEV1 < 50% predicted
- GOLD 4 (Very Severe): FEV1 < 30% predicted
- Pharmacotherapy (CTS Guidelines)
Initial Maintenance Therapy: Dual long-acting bronchodilator therapy with LAMA + LABA (e.g., Tiotropium/Olodaterol or Umeclidinium/Vilanterol) is preferred over monotherapy for patients with moderate-to-severe symptoms (CAT score ≥10 or mMRC ≥2) or a history of exacerbations.
Triple Therapy (LAMA + LABA + ICS): Recommended for patients who experience persistent exacerbations (≥2 moderate or ≥1 severe hospitalization per year) AND demonstrate blood eosinophil count ≥300 cells/µL.
Non-Pharmacological Interventions:
Smoking Cessation: The single most effective intervention to decrease the rate of FEV1 decline.
Vaccinations: Annual Influenza, Pneumococcal (PNEU-P-20 / PNEU-C-15), RSV, and COVID-19 vaccines.
Pulmonary Rehabilitation: Indicated for all symptomatic COPD patients.
Long-Term Oxygen Therapy (LTOT): Indicated if resting PaO2 ≤55 mmHg (SaO2 ≤88%), or PaO2 56–59 mmHg with evidence of cor pulmonale, right heart failure, or secondary polycythemia (hematocrit >55%). Administer ≥15 hours/day.
Acute Exacerbation of COPD (AECOPD)
Anthonisen Criteria for Antibiotics: (1) Increased dyspnea, (2) Increased sputum volume, (3) Increased sputum purulence. Antibiotics (Amoxicillin, Doxycycline, or Macrolide/Fluoroquinolone) are indicated if purulence + at least 1 other feature is present, or if requiring mechanical ventilation.
Oxygen Target: Administer controlled low-flow oxygen targeting SpO2 88–92% .
Exam Trap - Oxygen-Induced Hypercapnia: Uncontrolled high-flow O2 in severe COPD can precipitate severe CO2 retention and narcosis through: (1) Attenuation of hypoxic pulmonary vasoconstriction causing worsening V/Q mismatch, (2) The Haldane effect (de-oxygenated hemoglobin binds CO2 with higher affinity; oxygenation displaces CO2 into plasma), and (3) Decreased minute ventilation.
Acute Respiratory Failure (Type I vs. Type II)
- Feature Type I Respiratory Failure (Hypoxemic) Type II Respiratory Failure (Hypercapnic)
- Arterial Blood Gas Criteria PaO2 < 60 mmHg with normal or low PaCO2 PaCO2 > 45 mmHg with pH < 7.35
- Primary Pathophysiology V/Q Mismatch or Intrapulmonary Shunt Alveolar Hypoventilation
Common Etiologies Pneumonia, Pulmonary Edema, ARDS, PE, Atelectasis AECOPD, Severe Asthma, Opioid OD, ALS, Guillain-Barré
Initial Management High-flow O2, High-Flow Nasal Cannula (HFNC), CPAP Controlled O2 (target 88–92%), BiPAP (NIV)
Non-Invasive Positive Pressure Ventilation (BiPAP)
Indications: First-line therapy for acute hypercapnic respiratory failure in AECOPD presenting with respiratory acidosis (pH 7.25–7.35 and PaCO2 >45 mmHg), and acute cardiogenic pulmonary edema.
Contraindications: Respiratory arrest, uncooperative/encephalopathic patient, severe facial trauma/burns, high aspiration risk (vomiting, impaired airway reflexes), or hemodynamic instability/shock.